Literature DB >> 2063862

An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis.

J Rubin1, G A Herrera, D Collins.   

Abstract

Sixteen autopsies were performed on patients aged 56 +/- 15 (SD) years who were on continuous ambulatory peritoneal dialysis (CAPD) for 834 +/- 766 (SD) days. Lactate-buffered dialysate and povidone-iodine antiseptic were used in all cases. Multiple peritoneal sections were taken to evaluate peritoneal membrane thickening, inflammation, neovascularization, fibrosis, and adhesions. Peritoneal thickening, inflammation, or adhesions were not related to sex, race, or etiology of renal failure. Time on dialysis was also not a direct determinant of peritoneal adhesions or neovascularization. Peritonitis episodes correlated with chronic peritoneal serosal changes. This study supports the hypothesis that peritoneal alterations in patients on CAPD are related to episodes of peritonitis.

Entities:  

Mesh:

Year:  1991        PMID: 2063862     DOI: 10.1016/s0272-6386(12)80297-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

Review 1.  Peritoneal damage by peritoneal dialysis solutions.

Authors:  Takafumi Ito; Noriaki Yorioka
Journal:  Clin Exp Nephrol       Date:  2008-02-15       Impact factor: 2.801

2.  Ultrasonographic evaluation of peritoneal membrane thickness and comparison with the effectiveness and duration of CAPD.

Authors:  Gokhan Temiz; Garip Sahin; Gul Mukerrem; Sultan Ozkurt; Nevbahar Akcar Degirmenci; Ahmet Ugur Yalcin
Journal:  Int Urol Nephrol       Date:  2013-07-25       Impact factor: 2.370

Review 3.  Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

4.  Risks of peritoneal membrane failure in children undergoing long-term peritoneal dialysis.

Authors:  S P Andreoli; C D Langefeld; S Stadler; P Smith; A Sears; K West
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

5.  Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans.

Authors:  S Yung; G J Thomas; E Stylianou; J D Williams; G A Coles; M Davies
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

6.  Surgical management of peritoneal dialysis peritonitis: the impact of peritoneal sclerosis.

Authors:  Phillip J Yates; Jessica P A Kitchen; Monica Kaushik; Michael L Nicholson
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

7.  Encapsulating peritoneal sclerosis in an Italian center: thirty year experience.

Authors:  Valerio Vizzardi; Massimo Sandrini; Silvia Zecchini; Sara Ravera; Luigi Manili; Giovanni Cancarini
Journal:  J Nephrol       Date:  2015-10-31       Impact factor: 3.902

8.  Fibrinolysis in the peritoneal fluid during adhesions, endometriosis and ongoing pelvic inflammatory disease.

Authors:  G Edelstam; I Lecander; B Larsson; B Astedt
Journal:  Inflammation       Date:  1998-08       Impact factor: 4.092

9.  Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products.

Authors:  K N Lai; J C K Leung; L Y Y Chan; F F K Li; S C W Tang; M F Lam; K C Tse; T P Yip; T M Chan; A Wieslander; H Vlassara
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

10.  Are the Mesothelial-to-Mesenchymal Transition, Sclerotic Peritonitis Syndromes, and Encapsulating Peritoneal Sclerosis Part of the Same Process?

Authors:  Jesús Loureiro; Guadalupe Gónzalez-Mateo; José Jimenez-Heffernan; Rafael Selgas; Manuel López-Cabrera; Abelardo Aguilera Peralta
Journal:  Int J Nephrol       Date:  2013-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.